Symbiotic relationship of pharmacogenetics and drugs of abuse

No abstract is available for this paper.

• Publication year

  2006

• Venue

  AAPS Journal

• Publication date

  2006-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1208/aapsj080121PMID 16584126PMCID PMC2751437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of Functional Genetic Variation in the Dopamine D2 Receptor (DRD2) in Response to Bupropion and Nicotine Replacement Therapy for Tobacco Dependence: Results of Two Randomized Clinical Trials

  2006cited by this paper
• Homer Isoforms Differentially Regulate Cocaine-Induced Neuroplasticity

  2006cited by this paper
• Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments

  2005cited by this paper
• A functional glutathione S‐transferase P1 gene polymorphism is associated with methamphetamine‐induced psychosis in Japanese population

  2005cited by this paper
• The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans.

  2005cited by this paper
• Single- and multilocus allelic variants within the GABA(B) receptor subunit 2 (GABAB2) gene are significantly associated with nicotine dependence.

  2005cited by this paper
• Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene.

  2005cited by this paper
• The genetics of addictions: uncovering the genes

  2005cited by this paper
• Melanocortin-1 receptor gene variants affect pain and μ-opioid analgesia in mice and humans

  2005cited by this paper
• The role of the cannabinoid system in nicotine addiction.

  2005cited by this paper
• Dopamine Transporter Gene Associated with Diminished Subjective Response to Amphetamine

  2005cited by this paper
• Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR

  2005cited by this paper
• Will Nicotine Genetics and a Nicotine Vaccine Prevent Cigarette Smoking and Smoking-Related Diseases?

  2005cited by this paper
• Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder

  2005cited by this paper
• Safety and immunogenicity of a nicotine conjugate vaccine in current smokers

  2005cited by this paper
• Clinical response to morphine in cancer patients and genetic variation in candidate genes

  2005cited by this paper
• A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate

  2005cited by this paper
• COMT Polymorphisms and Anxiety-Related Personality Traits

  2005cited by this paper
• How individual sensitivity to opiates can be predicted by gene analyses.

  2005cited by this paper
• Dopamine Transporter Genotype and Methylphenidate Dose Response in Children with ADHD

  2005cited by this paper
• Health consequences of smoking 1–4 cigarettes per day

  2005cited by this paper
• Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G*

  2005cited by this paper
• The need for education in pharmacogenomics: a regulatory perspective

  2005cited by this paper
• Anti-nicotine vaccination: where are we?

  2005cited by this paper
• CB1 receptor antagonists for the treatment of nicotine addiction.

  2005cited by this paper
• Application of Information Technology: A Statistical Approach to Scanning the Biomedical Literature for Pharmacogenetics Knowledge

  2005cited by this paper
• Genetics and Drug Use as a Complex Phenotype

  2004cited by this paper
• Advances in pharmacotherapy for tobacco dependence.

  2004cited by this paper
• The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial

  2004cited by this paper
• A genomic scan for habitual smoking in families of alcoholics: Common and specific genetic factors in substance dependence

  2004cited by this paper
• Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations.

  2004cited by this paper
• Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden

  2004cited by this paper
• Setting Priorities for Genomic Research

  2004cited by this paper
• Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1

  2004cited by this paper
• The burden of complex genetics in brain disorders.

  2004cited by this paper
• Association analysis of the DRD4 and COMT genes in methamphetamine abuse

  2004cited by this paper
• Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament

  2004cited by this paper
• Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.

  2004cited by this paper
• Association analysis of dopamine D2-like receptor genes and methamphetamine abuse

  2004cited by this paper
• Effect of the A118G polymorphism on binding affinity, potency and agonist‐mediated endocytosis, desensitization, and resensitization of the human mu‐opioid receptor

  2004cited by this paper
• Alpha 4 beta 2* nicotinic acetylcholine receptors modulate the effects of ethanol and nicotine on the acoustic startle response.

  2003cited by this paper
• COMT val158met Genotype Affects µ-Opioid Neurotransmitter Responses to a Pain Stressor

  2003cited by this paper
• NicVAX (Nabi Biopharmaceuticals).

  2003cited by this paper
• New inroads in preventing adolescent drug use: results from a large-scale trial of project ALERT in middle schools.

  2003cited by this paper
• Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins.

  2003cited by this paper
• AMERICAN ATTITUDES TOWARD AND WILLINGNESS TO USE PSYCHIATRIC MEDICATIONS

  2003cited by this paper
• A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.

  2003cited by this paper
• Genomic Priorities and Public Health

  2003cited by this paper
• Will the genomics revolution revolutionize psychiatry?

  2003cited by this paper
• Genetics of alcohol and tobacco use in humans

  2003cited by this paper
• A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients

  2003cited by this paper
• A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins.

  2003cited by this paper
• The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans

  2003cited by this paper
• DAT's not all, but it may be more than we realize.

  2002cited by this paper
• The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine.

  2002cited by this paper
• Drug-metabolizing cytochrome P450s in the brain.

  2002cited by this paper
• Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study

  2002cited by this paper
• The genetics of tobacco use: methods, findings and policy implications

  2002cited by this paper
• Brief Research Communication Association of the Tryptophan Hydroxylase Gene With Smoking Initiation But Not Progression to Nicotine Dependence

  2001cited by this paper
• Bupropion for smoking cessation : predictors of successful outcome.

  2001cited by this paper
• Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.

  2001cited by this paper
• A Single Nucleotide Polymorphic Mutation in the Human μ-Opioid Receptor Severely Impairs Receptor Signaling*

  2001cited by this paper
• The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression

  2001cited by this paper
• Haplotypes at the DRD2 locus and severe alcoholism.

  2000cited by this paper
• Pharmacogenomics and addiction to opiates.

  2000cited by this paper
• Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers.

  2000cited by this paper
• Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking.

  2000cited by this paper
• Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: no interaction with functional alleles of the catechol-o-methyltransferase (COMT) gene.

  2000cited by this paper
• Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline.

  2000cited by this paper
• Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins.

  2000cited by this paper
• Genetics of two μ opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects

  1999cited by this paper
• An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient.

  1999cited by this paper
• No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans.

  1999cited by this paper
• Pharmacogenomics: translating functional genomics into rational therapeutics.

  1999cited by this paper
• Lack of an allelic association between polymorphisms of the dopamine D2 receptor gene and alcohol dependence in the German population.

  1999cited by this paper
• A genetic association for cigarette smoking behavior.

  1999cited by this paper
• D2 Dopamine Receptor Gene (DRD2) Allele and Haplotype Frequencies in Alcohol Dependent and Control Subjects: No Association with Phenotype or Severity of Phenotype

  1999cited by this paper
• Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians.

  1998cited by this paper
• Familial transmission of substance use disorders.

  1998cited by this paper
• The role of the serotonin transporter gene in cigarette smoking.

  1998cited by this paper
• Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

  1998cited by this paper
• Nicotine metabolism defect reduces smoking

  1998cited by this paper
• Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities.

  1998cited by this paper
• The dopamine D4 receptor gene (DRD4) is not associated with alcoholism in three Taiwanese populations: six polymorphisms tested separately and as haplotypes.

  1997cited by this paper
• Pain affect encoded in human anterior cingulate but not somatosensory cortex.

  1997cited by this paper
• Linkage and association of a functional DRD2 variant [Ser311Cys] and DRD2 markers to alcoholism, substance abuse and schizophrenia in Southwestern American Indians.

  1997cited by this paper
• Addiction is a brain disease, and it matters.

  1997cited by this paper
• Determinants of pressure pain threshold in adult twins: evidence that shared environmental influences predominate

  1997cited by this paper
• Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs.

  1996cited by this paper
• Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal.

  1996cited by this paper
• The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking.

  1996cited by this paper
• Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch.

  1996cited by this paper
• Morphine‐6‐glucuronide concentrations and opioid‐related side effects: a survey in cancer patients

  1995cited by this paper
• Genetic Association between Dopamine Transporter Protein Alleles and Cocaine-Induced Paranoia

  1995cited by this paper
• Smoking and death: the past 40 years and the next 40

  1994cited by this paper
• Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties.

  1994cited by this paper
• Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women.

  1994cited by this paper
• The effectiveness of the nicotine patch for smoking cessation. A meta-analysis.

  1994cited by this paper
• Genetic Association between Dopamine Transporter Protein Alleles and Cocaine-Induced Paranoia

  1994cited by this paper
• Smoking Cessation and Time Course of Decreased Risks of Coronary Heart Disease in Middle-Aged Women

  1994cited by this paper

• OPRM1 rs2075572 has potential to affect plasma buprenorphine level in opioid users, but not OPRM1 rs562859.

  2024cites this paper
• Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders

  2019cites this paper
• The Neuroscience of Drug Reward and Addiction.

  2019cites this paper
• Pharmacogenomics of Drugs of Abuse

  2019cites this paper
• Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How

  2018cites this paper
• Pathways to precision medicine in smoking cessation treatments.

  2016cites this paper
• Association between genetic variations of NMDA receptor NR3 subfamily genes and heroin addiction in male Han Chinese.

  2016cites this paper
• The Genetics of Addiction: A Global Problem with Global Opportunities

  2015cites this paper
• Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.

  2015cites this paper
• enetic variation ( CHRNA 5 ) , medication ( combination nicotine eplacement therapy vs . varenicline ) , and smoking cessation

  2015cites this paper
• Addiction science: Uncovering neurobiological complexity.

  2014cites this paper
• Re-defininG AddiCCH3Tion: genomics and epigenomics on substance use disorders

  2014cites this paper
• Dopamine D2 receptor and ankyrin repeat and kinase domain containing 1 genes among the two linguistically distinct tribal populations of Ranchi district, Jharkhand, India.

  2013cites this paper
• Positive association between--1021TT genotype of dopamine beta hydroxylase gene and progressive behavior of injection heroin users.

  2013cites this paper
• Genomics and personalized medicine: CHRNA5-CHRNA3-CHRNB4 and smoking cessation treatment.

  2013cites this paper
• Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.

  2012cites this paper
• Pharmacogenomics of Cocaine

  2012cites this paper
• Pharmacogenomics Principles of Alcohol and DOA

  2012cites this paper
• isk Fac to rs ( CHRNA 5-CHRNA 3-CHRNB 4 ) and Ce ssa

  2012cites this paper
• Pharmacotherapy of Addiction

  2012cites this paper
• Addiction as a systems failure: focus on adolescence and smoking.

  2011cites this paper
• Ethical Concerns Related to Developing Pharmacogenomic Treatment Strategies for Addiction

  2011cites this paper
• Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects

  2011influential citation
• Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment.

  2010cites this paper
• Pharmacotherapy of Cocaine Addiction

  2010cites this paper
• Pharmacogenetics: A Tool for Identifying Genetic Factors in Drug Dependence and Response to Treatment

  2010cites this paper
• Frontiers in addiction research: celebrating the 35th anniversary of the National Institute on Drug Abuse. Sponsor's foreword.

  2009cites this paper
• New insights into the genetics of addiction

  2009cites this paper
• Personalized Management of Miscellaneous Disorders

  2009cites this paper
• Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.

  2009cites this paper
• Genetic Influences on Addiction

  2009cites this paper
• The effect of DHEA complementary treatment on heroin addicts participating in a rehabilitation program: a preliminary study.

  2008cites this paper
• Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment

  2008cites this paper
• Indolealkylamines: Biotransformations and Potential Drug–Drug Interactions

  2008cites this paper
• Unintentional drug overdose death trends in New Mexico, USA, 1990-2005: combinations of heroin, cocaine, prescription opioids and alcohol.

  2008cites this paper
• Anticipating Clinical Integration of Pharmacogenetic Treatment Strategies for Addiction: Are Primary Care Physicians Ready?

  2008cites this paper
• Translational research in medication development for nicotine dependence

  2007cites this paper
• Genetics and smoking cessation improving outcomes in smokers at risk.

  2007cites this paper
• Developing consensus on tobacco control and research.

  2007cites this paper